Investigational / not FDA-approved

VIP

Vasoactive intestinal peptide — ≠ PACAP; inhaled sarcoid/PH exploratory.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. VIP is the 28-amino-acid neuropeptide vasoactive intestinal peptide. PubChem CID 53314964; formula C147H237N43O43S / MW 3326.8; CAS 37221-79-7. Closely related to PACAP family peptides — VIP ≠ PACAP. Endogenous hormone / neuropeptide with receptors VPAC1/VPAC2. Labeled diagnostic/therapeutic contexts are limited and indication-specific (e.g. VIPoma biology); investigational inhaled VIP has been studied in pulmonary disease. This drawer marks papers. It is not use advice.

Bottom line

Best-characterized human interventional signals in this pack are inhaled VIP exploratory work in sarcoidosis (immunoregulatory effects) and pulmonary hypertension, plus older erectile-injection pilots. Broader literature covers VIP/PACAP biology, pulmonary disease reviews, cancer/VIPoma overviews. Refuse “universal healing peptide” glow.

Papers

Inhaled / pulmonary human-relevant

PMID 20442436 — Prasse 2010

Tested: inhaled VIP exerts immunoregulatory effects in sarcoidosis (human interventional study).

Does not show: a broadly approved sarcoidosis VIP drug product in all jurisdictions, or systemic wellness use.

PMID 18978135 — Leuchte 2008

Tested: inhalation of VIP in pulmonary hypertension.

Does not show: that unlabeled VIP vials equal trial inhaled material.

PMID 23935337 — Mathioudakis 2013

Tested: review of inhaled VIP agonists’ potential role in respiratory therapeutics.

Does not show: a new primary pivotal trial.

PMID 37742737 — Zhong 2023

Tested: review of VIP’s role in pulmonary diseases.

Does not show: new primary clinical efficacy data by itself.

Biology / oncology context

PMID 19859678 — Fahrenkrug 2010

Tested: review of VIP and PACAP biology.

Does not show: clinical approval of exogenous VIP peptide for general use.

PMID 26702849 — Moody 2016

Tested: VIP/PACAP and receptors in cancer framing.

Does not show: approved VIP anticancer therapy.

PMID 31609932 — Siddappa 2019

Tested: review of VIP-secreting tumors (VIPomas).

Does not show: that exogenous VIP is a treatment for VIPoma (pathophysiology context).

Older interventional pilot

PMID 2405186 — Roy 1990

Tested: clinical trial of intracavernous VIP to induce penile erection.

Does not show: a modern first-line ED standard or systemic peptide wellness claim.

What is not established

Broad approved indications for exogenous VIP as a consumer or “research vial” peptide. Equivalence of unlabeled VIP to inhaled trial formulations. Interchangeability with PACAP. This drawer does not provide use advice, schedules, or sourcing.

Selected sources

20442436 18978135 23935337 37742737 19859678 26702849 31609932 2405186

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.